PlainPharmaWatch

CMS Open Payments · Tool

Omnia Medical, LLC vs Calliditas Therapeutics US Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Omnia Medical, LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,054, versus 169 for the other company. Its single largest recorded recipient represents 17.8% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Omnia Medical, LLC
HHI 1,054 · top recipient 17.8%
Ranked #1,007 of 1,838 companies by HHI
Calliditas Therapeutics US Inc.
HHI 169 · top recipient 6.2%
Ranked #1,593 of 1,838 companies by HHI

Payment Overview

Company A

Omnia Medical, LLC

Total Payments
$2.0M
% of Industry
0.0%
Transactions
110
Avg per Transaction
$18.3K
Recipients
110
Avg per Recipient
$18.3K
Payment Types
3
Top Payment Type
Acquisitions
Total Payments
$2.0M
% of Industry
0.0%
Transactions
12,052
Avg per Transaction
$165.74
Recipients
12,051
Avg per Recipient
$165.75
Payment Types
6
Top Payment Type
Honoraria

Highlighted values indicate the higher figure for each metric.

Total payments compared

Omnia Medical, LLC vs Calliditas Therapeutics US Inc. - total reported payments in CMS Open Payments PY2024

Omnia Medical, LLC$2.0MCalliditas Therapeutics US…$2.0M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Omnia Medical, LLC

Acquisitions $1.4M

68.8%

Royalty or License $530.1K

26.3%

Consulting Fee $99.1K

4.9%

Calliditas Therapeutics US Inc.

Honoraria $878.3K

44.2%

Consulting Fee $472.9K

23.8%

Food and Beverage $353.3K

17.8%

Travel and Lodging $280.4K

14.1%

Space Rental or Facility Fees $1.5K

0.1%

Education $250.00

0.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Omnia Medical, LLC

  1. 1

    JOHN MAIN

    $360,000.00 · 12 txns

  2. 2

    BRIAN SNELL

    $297,000.00 · 1 txns

  3. 3

    ANDREW PARKINSON

    $252,879.70 · 10 txns

  4. 4

    IAN JOHNSON

    $240,000.00 · 4 txns

  5. 5

    JUSTIN FIELD

    $168,833.36 · 7 txns

Calliditas Therapeutics US Inc.

  1. 1

    GERALD BERNARD APPEL

    $122,899.83 · 94 txns

  2. 2

    JORGE ANTONIO LARRANAGA

    $106,250.71 · 102 txns

  3. 3

    SREEDHAR A MANDAYAM

    $74,332.61 · 97 txns

  4. 4

    ANIS A RAUF

    $69,181.56 · 80 txns

  5. 5

    SAYNA NOROUZI

    $68,439.72 · 58 txns

Summary Comparison

Metric Omnia Medical, LLC Calliditas Therapeutics US Inc.
Total Payments $2.0M $2.0M
% of Industry Total 0.0% 0.0%
Transaction Count 110 12,052
Avg per Transaction $18.3K $165.74
Recipient Count 110 12,051
Avg per Recipient $18.3K $165.75
Payment Type Count 3 6
Top Payment Type Acquisitions Honoraria

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.